The incurable neurodegenerative Alzheimer’s disease has long been associated with β-amyloid build-up in the brain. While this has been known, direct evidence supporting the close relationship of Alzheimer’s disease and the role of β-amyloid has been hard to come by, until now. Recent Aβ-immunotherapy trials have shown that removing aggregated β-amyloid from symptomatic patients can slow down the disease.

β-amyloid removal slows the progression of Alzheimer’s disease

This breakthrough holds many implications for future treatment and handling of Alzheimer’s disease. While the new evidence is far from being a cure itself, it presents the opportunity for long-term prevention and potential immunoprevention towards the disease. This is in part due to how early the signs and abnormal β-amyloid build-up can begin in Alzheimer’s patients, as well as how complex the disease itself can become. However many clinical trials and experiments it may take, groups like LifeTein will always be ready to help supply researchers with the materials they need to make this future possible.

Jucker, M., & Walker, L. C. (2023). Alzheimer’s disease: From immunotherapy to immunoprevention. In Cell (Vol. 186, Issue 20, pp. 4260–4270). Elsevier BV. https://doi.org/10.1016/j.cell.2023.08.021